Novo Nordisk Investigational Site

Bornova-IZMIR 35100

0 studies enrolling now · 14 studies all time

What they study most

Congenital Bleeding Disorder, Haemophilia A, Haemophilia A With Inhibitors, Haemophilia B, Haemophilia B With Inhibitors, Haemostasis

Studies at this site

• A Research Study Looking at How a Factor VIII Medicine Called Turoctocog Alfa Pegol (N8-GP) Works in People With Haemophilia A — Completed
• A Study Following People With Haemophilia A and B, With or Without Inhibitors, When on Usual Treatment (Explorer™6) — Completed
• A Trial Evaluating Efficacy and Safety of Prophylactic Administration of Concizumab in Patients With Severe Haemophilia A Without Inhibitors — Completed
• Safety and Efficacy of Turoctocog Alfa in Prevention and Treatment of Bleeds in Previously Untreated Children With Haemophilia A — Completed
• Evaluation of Safety and Efficacy, Including Pharmacokinetics, of NNC 0129-0000-1003 When Administered for Treatment and Prophylaxis of Bleeding in Subjects With Haemophilia A — Completed
• A Multinational, Open-Label, Non-Controlled Trial on Safety, Efficacy and Pharmacokinetics of NNC 0129-0000-1003 in Previously Treated Paediatric Patients With Severe Haemophilia A — Completed
• Evaluating the Haemostatic Effect of NNC 0129-0000-1003 During Surgical Procedures in Subjects With Haemophilia A. — Completed
• Safety and Efficacy of Turoctocog Alfa (N8) in Prevention and On-demand Treatment of Bleeding Episodes in Subjects With Haemophilia A: An Extension to Trials NN7008-3543, NN7008-3545, NN7008-3600, NN7008-3893 and NN7008-4015 — Completed
• Trial Investigating Safety, Pharmacokinetics and Pharmacodynamics of Concizumab Administered Subcutaneously to Haemophilia A Subjects — Completed
• Safety and Efficacy of Turoctocog Alfa in Previously Treated Male Children With Haemophilia A — Completed
• Safety and Efficacy of Turoctocog Alfa in Haemophilia A Subjects — Completed
• Haemophilia Patients With Inhibitors Being Treated for Acute Joint Bleeds — Completed
• Safety and Pharmacokinetics of NNC 0129-0000-1003 in Subjects With Haemophilia A — Completed
• Efficacy of NovoSeven® in Bleeding Prophylaxis in Hemophilia — Completed